New models help predict liver cancer after successful hepatitis C virus (HCV) treatment
(Spink Health) Digital ILC 2020: European scientists develop new predictive models for HCC in patients with chronic HCV after a sustained virological response to direct-acting antiviral therapy (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 26, 2020 Category: Cancer & Oncology Source Type: news

HCV Relapse After Successful Treatment With DAAs HCV Relapse After Successful Treatment With DAAs
HCV recurred in this patient 6 months after achieving SVR with direct-acting antiviral therapy, along with a sarcomatous change in HCC. What might be the relationship between these events?Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 15, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Triple Antiviral Therapy Promising for Mild-to-Moderate COVID-19
MONDAY, May 11, 2020 -- For patients with COVID-19, early triple antiviral therapy (lopinavir-ritonavir, ribavirin, and interferon beta-1b) is better than lopinavir-ritonavir for reducing the time to providing a nasopharyngeal swab negative for... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 11, 2020 Category: Pharmaceuticals Source Type: news

New triple antiviral drug combination shows early promise for treating COVID-19 in phase 2 randomized trial
A two-week course of antiviral therapy with interferon beta-1b plus lopinavir-ritonavir and ribavirin, started within 7 days of showing COVID-19 symptoms, is safe and more effective at reducing the duration of viral shedding than lopinavir-ritonavir alone in patients with mild to moderate illness, according to the first randomised trial of this triple combination therapy involving 127 adults (aged 18 and older) from six public hospitals in Hong Kong. (Source: World Pharma News)
Source: World Pharma News - May 11, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Why Infectious Diseases Like COVID-19 Make Science Move So Fast
This article is part of #TIME100Talks: Finding Hope, a special series featuring leaders across different fields sharing their ideas for navigating the pandemic. Want more? Sign up for access to more virtual events, including live conversations with influential newsmakers. (Source: TIME: Health)
Source: TIME: Health - May 8, 2020 Category: Consumer Health News Authors: Mandy Oaklander Tags: Uncategorized COVID-19 TIME 100 TIME100 Talks video Source Type: news

The Lancet: New triple antiviral drug combination shows early promise for treating COVID-19 in phase 2 randomized trial
(The Lancet) A two-week course of antiviral therapy with interferon beta-1b plus lopinavir-ritonavir and ribavirin, started within 7 days of showing COVID-19 symptoms, is safe and more effective at reducing the duration of viral shedding than lopinavir-ritonavir alone in patients with mild to moderate illness, according to the first randomized trial of this triple combination therapy involving 127 adults (aged 18 and older) from six public hospitals in Hong Kong. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 8, 2020 Category: Infectious Diseases Source Type: news

Model Shows Hep C-Infected Kidney Transplants Beneficial, Cost-Effective
MONDAY, April 6, 2020 -- Transplanting hepatitis C virus (HCV)-infected kidneys into uninfected recipients and then treating patients with antiviral therapy leads to a higher quality of life and is less costly than waiting for transplantation with... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 6, 2020 Category: Pharmaceuticals Source Type: news

FDA Gives Nod for Breakthrough HIV Test
Vela Diagnostics will go down in history as bringing to market the first test capable of detecting human immunodeficiency virus (HIV) Type-1 drug resistance mutations using next-generation sequencing (NGS) technology. The Fairfield, NJ-based company submitted the Sentosa SQ HIV Genotyping Assay for FDA market authorization in March. It is the first FDA-authorized HIV drug resistance assay that uses NGS technology. “The ability to rationally select treatments for patients about to start or already taking antiviral therapy provides another tool in our ongoing ...
Source: MDDI - November 6, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: IVD Source Type: news

' Curing' Hepatitis C Is Not the End of Patient Care'Curing' Hepatitis C Is Not the End of Patient Care
Antiviral therapy has given patients with hepatitis C infection a new lease on life, but the risk for cancer and reinfection means they still require continued monitoring.Medscape Gastroenterology (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - August 12, 2019 Category: Gastroenterology Tags: Gastroenterology Article Source Type: news

Parkinson Disease Incidence Lower in Hep C Patients Who Receive Antivirals
THURSDAY, June 6, 2019 -- The incidence of Parkinson disease (PD) is lower for patients with chronic hepatitis C virus (HCV) infection who receive interferon-based antiviral therapy, according to a study published online June 5 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 6, 2019 Category: Pharmaceuticals Source Type: news

Discarded No More: HCV-Infected Organs Advance Transplantation Discarded No More: HCV-Infected Organs Advance Transplantation
Direct-acting antiviral therapy has made the use of HCV-infected organs a reality. Here is an inside look at one liver transplant program as they deliberate this option for their patients.Medscape Gastroenterology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 3, 2019 Category: Allergy & Immunology Tags: Gastroenterology Commentary Source Type: news

Antiviral therapy improves survival rates for kidney transplant recipients with hepatitis B or C
(Elsevier) Prior to the development of antiviral therapy, kidney transplant recipients infected with either hepatitis B (HBV) or hepatitis C (HCV) experienced poor outcomes. In a new study in the Journal of Hepatology, published by Elsevier, researchers report favorable 10-year survival rates for patients with HBV and/or HCV treated with antiviral agents and advise that antiviral therapy should be systematically offered to all HBV and HCV patients in line with international recommendations. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 14, 2019 Category: Infectious Diseases Source Type: news

Early Antiviral Therapy and Lymphoma Risk in Chronic HCV Early Antiviral Therapy and Lymphoma Risk in Chronic HCV
Chronic HCV infection has been linked to lymphoproliferative disorders. Can early PegIFN/RBV therapy reduce the risk?Alimentary Pharmacology & Therapeutics (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - March 13, 2019 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news

Liver Transplant Listing for HCV-associated Cirrhosis and HCC Liver Transplant Listing for HCV-associated Cirrhosis and HCC
How has the availability of direct-acting antiviral therapy impacted liver transplantation indications and waiting list outcomes in patients with chronic hepatitis C?Journal of Viral Hepatitis (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - March 6, 2019 Category: Transplant Surgery Tags: Gastroenterology Journal Article Source Type: news

Stopping Oral Antiviral Therapy in Chronic Hep B Possible for Some People Stopping Oral Antiviral Therapy in Chronic Hep B Possible for Some People
A new analysis provides insight into what happens after stopping tenofovir disoproxil fumarate (TDF) in chronic hepatitis B patients with persistent viral suppression who took the drug for at least eight years.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 1, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Treating shingles after it appears doesn't reduce increased stroke risk
(American Heart Association) Stroke risk increased significantly in the days, weeks and months after shingles appeared, despite use of the shingles vaccine and antiviral therapy to treat it, according to preliminary research. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 30, 2019 Category: International Medicine & Public Health Source Type: news

Liver Cancer Recurrence Not Linked to Hepatitis Treatment Liver Cancer Recurrence Not Linked to Hepatitis Treatment
Patients with liver cancer related to hepatitis C infection should be considered for antiviral therapy with direct-acting antiviral therapies, say researchers.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 24, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes
Medicines and Healthcare products Regulatory Agency(MHRA) has issued a safety alert advising to monitor glucose levels closely in patients with diabetes during direct-acting antiviral therapy for hepa (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - December 21, 2018 Category: Drugs & Pharmacology Source Type: news

Option Found for Retreatment of Chronic Hep C Infection
THURSDAY, Nov. 15, 2018 -- Combined treatment with glecaprevir and pibrentasvir (G/P) is highly effective in treating chronic hepatitis C virus (HCV) genotype-1 infections that failed to respond to direct-acting antiviral therapy, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 15, 2018 Category: Pharmaceuticals Source Type: news

Hepatitis C Treatment Options: 5 Direct Questions
An HCV-infected patient who still injects drugs wants to start direct-acting antiviral therapy. What do guidelines recommend? (Source: ConsultantLive)
Source: ConsultantLive - November 14, 2018 Category: Internal Medicine Authors: Andrew Bowser Tags: Hepatitis C Source Type: news

HCV-Infected Kidney Waitlist Patients: Treat Now or Later? HCV-Infected Kidney Waitlist Patients: Treat Now or Later?
Which factors should be considered in the decision to initiate early or deferred direct-acting antiviral therapy among HCV-positive waitlisted patients?American Journal of Transplantation (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - November 1, 2018 Category: Surgery Tags: Nephrology Journal Article Source Type: news

Direct-acting antiviral therapy for hepatitis  C saves costs in Italy
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2018 Category: Drugs & Pharmacology Source Type: news

Eight Weeks of Antiviral Therapy for Recent HCV Infection Eight Weeks of Antiviral Therapy for Recent HCV Infection
Is an 8-week therapy of paritaprevir/ritonavir/ombitasvir and dasabuvir + ribavirin as effective as the standard 12-week regimen in individuals with recent HCV infection?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 17, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Preemptive DAAs for HCV+ Donor Livers Found Cost Effective
(MedPage Today) -- Direct-acting antiviral therapy in seronegative liver recipients could shorten transplant waiting lists (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - August 25, 2018 Category: Gastroenterology Source Type: news

Recurrence of HCC Following Direct-acting Antiviral Therapy Recurrence of HCC Following Direct-acting Antiviral Therapy
Might direct-acting antivirals increase risk and aggressiveness of hepatocellular carcinoma recurrence? This review aimed to characterize HCC recurrence patterns after DAA therapy.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 23, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Direct Antiviral Therapy of Hep C May Not Boost Hepatocellular-Carcinoma Risk Direct Antiviral Therapy of Hep C May Not Boost Hepatocellular-Carcinoma Risk
Treatment of hepatitis C (HCV) with direct-acting antiviral agents does not appear to increase the risk of hepatocellular carcinoma (HCC) in individuals with cirrhosis, researchers from France report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 3, 2018 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

Hep C Expert Interview: Gregory T. Everson, MD
Renowned transplant expert Gregory T. Everson, MD, talked with Patient Care about sensitive issues surrounding liver transplant in the era of direct-acting antiviral therapy. (Source: ConsultantLive)
Source: ConsultantLive - August 1, 2018 Category: Internal Medicine Authors: Andrew D. Bowser Tags: Hepatitis C Source Type: news

HCV: 6 Reasons in Favor of Antiviral Therapy During Pregnancy HCV: 6 Reasons in Favor of Antiviral Therapy During Pregnancy
Dr Nancy Reau discusses factors that could potentially support the use of antiviral therapy during pregnancy to prevent mother-to-child transmission of hepatitis C virus infection.Medscape Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 23, 2018 Category: Consumer Health News Tags: Gastroenterology Commentary Source Type: news

Negative rapid test results may delay antiviral therapy in patients with severe influenza
(American Society for Microbiology) A new study has found that half of influenza cases in patients admitted to the intensive care unit (ICU) received a false negative rapid influenza antigen test (RIAT). The false negative RIAT results could delay antiviral therapy for patients who were in the ICU with severe influenza. The research is presented at ASM Microbe, the American Society for Microbiology's annual meeting, held from June 7-11 in Atlanta, Ga. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 10, 2018 Category: Biology Source Type: news

Liver Stiffness Measurement-Based Approach for HBV Liver Stiffness Measurement-Based Approach for HBV
Decline of liver stiffness from baseline after 1 year of antiviral therapy for HBV infection may reflect remission of liver inflammation and fibrosis.Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 3, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

HBV Treatment Fails to Meet Global Targets (CME/CE)
(MedPage Today) -- Only 5% of hepatitis B patients received antiviral therapy in 2016 (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 27, 2018 Category: Primary Care Source Type: news

Treatment To Prevent Hepatitis C Recurrence After Liver Transplantation
In a clinical trial, researchers found that antiviral therapy prior to a liver transplant can prevent hepatitis C recurrence in some patients. (Source: NIDDK News)
Source: NIDDK News - March 15, 2018 Category: Endocrinology Source Type: news

Hepatitis C Virus Clearance in Older Adults Hepatitis C Virus Clearance in Older Adults
Does HCV clearance with direct-acting antiviral therapy improve outcomes in individuals aged 80 and older--even in the face of severe liver disease and multiple comorbidities?Journal of the American Geriatrics Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 21, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Shortening Duration of Therapy With DAAs for HCV Genotype 1 Shortening Duration of Therapy With DAAs for HCV Genotype 1
Can direct-acting antiviral therapy for hepatitis C genotype 1 be reduced to less than the current standard of 12 weeks without compromising outcomes?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 9, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Sofosbuvir Safe, Effective for HCV in Those With CKD Sofosbuvir Safe, Effective for HCV in Those With CKD
Sofosbuvir-based antiviral therapy cured hepatitis C virus infection in more than 80% of patients with chronic kidney disease, a retrospective cohort study found.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 15, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Treating a little-known virus, CMV, to combat hearing loss in children
(University of Utah Health) A National Institutes of Health-supported nationwide clinical trial will test a novel approach to combat hearing loss in children infected by a relatively unknown virus, cytomegalovirus (CMV). The University of Utah Health-led study will determine whether antiviral therapy can halt progressive hearing loss in children with a confirmed CMV infection. CMV is the leading non-genetic cause of hearing loss, contributing from 6 to 30 percent of childhood cases. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 14, 2017 Category: Infectious Diseases Source Type: news

Antiviral Therapy in Patients With Influenza Antiviral Therapy in Patients With Influenza
Which patients should receive antiviral therapy for influenza, and what are the currently available options?U.S. Pharmacist (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 22, 2017 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news

Subcirrhotic Liver Stiffness Cuts HCC Risk in Hepatitis B
Achievement of subcirrhotic range of liver stiffness with antiviral therapy reduces HCC risk (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 10, 2017 Category: Cancer & Oncology Tags: Gastroenterology, Infections, Internal Medicine, Oncology, Journal, Source Type: news

Antiviral therapy is effective in fighting hepatitis C | Letters
The Cochrane analysis casting doubt on this life-saving therapy is flawed and may deter patients from seeking it, say clinicians and scientistsWe are clinicians and scientists who have studied and treated patients with chronic hepatitis C virus infection over many years and patient groups that represent those affected by hepatitis C. We write in response to your article on the effectiveness of antiviral therapy (Hepatitis ‘wonder drug’ may be clinically ineffective, say experts, 9 June). The Cochrane review that you highlight analysed clinical trials, which are by nature short term, where the sole purpose was t...
Source: Guardian Unlimited Science - June 13, 2017 Category: Science Authors: Letters Tags: Hepatitis C Health Pharmaceuticals industry Medical research Drugs Business Science UK news Society Source Type: news

The Potential Role of Polymerase Chain Reaction in Diagnosis of Neonatal Herpes Simplex Virus Infection: Is Viral Culture Outdated?
Even in the era of effective antiviral therapy, neonatal herpes simplex viral infection causes significant morbidity and mortality in newborns. Prompt diagnosis is the cornerstone of treatment of these infants. Outside and inside the neonatal clinical practice, polymerase chain reaction (PCR) is replacing culture as a method of facilitating a speedy diagnosis of herpes simplex virus infection. New pediatric guidelines call for testing of high-risk asymptomatic infants, and thus, many more surface cultures and PCRs are being performed. (Source: Clinical Microbiology Newsletter)
Source: Clinical Microbiology Newsletter - June 6, 2017 Category: Microbiology Authors: Nicole L. Samies, Swathi M. Gowtham Source Type: news

IRE1{alpha} promotes viral infection by conferring resistance to apoptosis
The unfolded protein response (UPR) is an ancient cellular pathway that detects and alleviates protein-folding stresses. The UPR components X-box binding protein 1 (XBP1) and inositol-requiring enzyme 1α (IRE1α) promote type I interferon (IFN) responses. We found that Xbp1-deficient mouse embryonic fibroblasts and macrophages had impaired antiviral resistance. However, this was not because of a defect in type I IFN responses but rather an inability of Xbp1-deficient cells to undergo viral-induced apoptosis. The ability to undergo apoptosis limited infection in wild-type cells. Xbp1-deficient cells were generall...
Source: Signal Transduction Knowledge Environment - June 6, 2017 Category: Science Authors: Fink, S. L., Jayewickreme, T. R., Molony, R. D., Iwawaki, T., Landis, C. S., Lindenbach, B. D., Iwasaki, A. Tags: STKE Research Articles Source Type: news

Risk of HBV Reactivation in Patients on Antivirals for HCV Risk of HBV Reactivation in Patients on Antivirals for HCV
Is there a clinically relevant risk of HBV reactivation during direct-acting antiviral therapy for HCV with an interferon-free regimen?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 23, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

HBIG Plus Antivirals May Prevent HBV Reinfection After Transplant HBIG Plus Antivirals May Prevent HBV Reinfection After Transplant
A very short course of hepatitis B immunoglobulin (HBIG) after liver transplantation, along with long-term antiviral therapy, may prevent hepatitis B virus (HBV) reinfection, a retrospective study suggests.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - May 22, 2017 Category: Transplant Surgery Tags: Transplantation News Source Type: news

Prevalence and Impact of Steatohepatitis in HBV Patients Prevalence and Impact of Steatohepatitis in HBV Patients
This study assessed the prevalence of steatohepatitis in chronic HBV-infected patients, its risk factors, and its correlation with liver fibrosis and response to antiviral therapy.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 9, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C
Dateline City: KENILWORTH, N.J. Findings Presented at The International Liver Congress ™ 2017 Show High Rates of Sustained Virologic Response (SVR12) in Genotype 1 Patients for Whom Direct-Acting Antiviral Therapy Had Previously FailedKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first sustained virologic response1 (SVR) results 12 weeks after completion of therapy (SVR12, considered virologic cure) fromC-SURGE, an ongoing, open label Phase 2 clinical trial evaluating MK-3682B [uprifosbuvir (MK-3682)2/grazoprevir3...
Source: Merck.com - Research and Development News - April 22, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Hepatitis C MSD NYSE:MRK Source Type: news

Hepatitis C treatment can be provided successfully at syringe programme sites
Administering direct-acting antiviral therapy for people who inject drugs at a syringe exchange site led to high sustained response rates in a pilot study in New York City. (Source: PHPartners.org)
Source: PHPartners.org - April 19, 2017 Category: Global & Universal Source Type: news

Poor Adherence to Antiviral Treatment for Hepatitis B Poor Adherence to Antiviral Treatment for Hepatitis B
Antiviral therapy for hepatitis B is effective and improves outcomes, but is often long-term, and adherence can be poor. What factors might influence non-adherence to therapy?Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - February 9, 2017 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news